Naloxone Grant Opportunity



Naloxone Grant Opportunity for Local Health Departments Now Open

February 2024; Updated April 2025

Project Description

The Indiana Department of Health (IDOH) is accepting applications from local health departments (LHDs) in response to the grant opportunity for the distribution of opioid overdose reversal kits that include naloxone nasal spray. IDOH will be responsible for awarding the number of overdose reversal kits and is partnering with Overdose Lifeline to distribute the kits to LHDs. LHDs will be responsible for the distribution of kits in their communities.

Naloxone hydrochloride is an opioid antagonist and a safe and effective medication used to quickly reverse the life-threatening effects of an opioid overdose. The naloxone kits distributed in accordance with this grant will be administered intranasally by spraying a fine mist up the nostril of the affected person.

The goal of this grant is to expand the number of LHDs that participate in the distribution of opioid overdose reversal kits. LHDs are highly encouraged to collaborate with community organizations, including county jails, for this opportunity. Jails in the county will be able to receive naloxone kits through the LHD to give to incarcerated persons upon their release.

This effort will require providing education about naloxone kit programs and the law that provides immunity for lay responders to carry and administer the life-saving medication. Lay responders who agree to participate in a naloxone kit program must be trained by the awardee on how to administer naloxone (if not previously trained).

Service Delivery

The services will be implemented beginning February 2024. Failure to comply with all terms of this grant will halt any future awarded, but unshipped, naloxone kits.

Failure to comply includes:

- Not submitting required reports within the required time period
- Not distributing the naloxone kits as outlined in the application
- Distributing naloxone kits without ensuring lay responders are properly trained
- Selling the kits instead of distributing them free of charge
- Not registering with OptIN
- Inaccurate reporting of the distribution of naloxone kits
- Loss of naloxone kits

Funding

All grants are contingent upon the availability of funding. The funding for this program is provided by the Family and Social Services Administration, Division of Mental Health and Addiction through State Opioid Response funding. Individual awardee naloxone kit totals will be determined based on the geographic service area and the need identified by the awardee.

IDOH recommends applicants reach out to other local agencies to see if they are interested in receiving naloxone from the health department through this grant. In the past, health departments have reached out to faith-based organizations, public libraries, homeless shelters, schools, etc. These agencies provided the health department with the number of naloxone kits they would need, and the health department factored those numbers into the total number of kits they requested.

Applicants are encouraged to apply at their earliest convenience. Overdose reversal kits will be awarded on an ongoing basis. Each application will be capped at 6,000 individual kits. If an LHD needs more than 6,000 kits, they will be eligible to re-apply once they have distributed at least 75% (4,500) of the 6,000 kits. Kits will be awarded based on community need as determined by statewide opioid and overdose data.

Eligibility

- Respondents must be either:
 - Local health departments
 - Entities that serve Native American/Indigenous populations (including those who
 do not live on reservation land)
 - Any non-LHD community organization wishing to apply for overdose reversal kits will need to apply through Overdose Lifeline at www.OverdoseLifeline.org
- Respondents must be able to provide training on the administration of naloxone prior to distribution.
- Respondents must be able to provide addiction treatment and referral information for treatment programs when distributing the naloxone kits.
- Respondents must register as a distribution entity on OptIN.

Awardee Participation Guidelines

- The awardee must not charge the receivers of the naloxone kits and must ensure that naloxone kits are not resold after distribution.
- The awardee must provide adequate education when distributing naloxone kits in a manner consistent with I.C. 16-42-27 and provide documentation thereof.
- The awardee must provide treatment program contact information for the community when distributing naloxone.
- The awardee must register with OptIN.
- If the awardee's point of contact changes anytime during the naloxone kit distribution or reporting period, the awardee must notify the department within 5 business days after the change and provide the contact information for the new contact.
- The awardee must submit distribution reports to continue receiving overdose reversal kits containing naloxone. According to the instructions received upon award.
- The awardee may not use kits from this funding to fill or refill naloxone vending machines.

Grant Application

- The application will be online in REDCap. Applicants will not have the option to submit a PDF or Word document.
- Applicants must address all the questions in the application.
- It is recommended that the grant application be completed in one sitting.



- If an applicant needs to complete part of the application at a later date, click the Save & Return button at the bottom of the REDCap screen. The applicant must keep record of their unique survey code.
- When applicants return to the link to complete an unfinished application, they must click
 the returning button in the upper-right corner. The applicant will then enter their unique
 survey code.
- If an applicant has misplaced their unique survey code, they should contact the naloxone program manager.
- Once the application is submitted, it cannot be edited.
- REDCap application link: https://redcap.isdh.in.gov/surveys/?s=JNA9CJ34N84FFXF7

Delivery of Naloxone and Reporting Requirements

Once IDOH has notified the LHD of their award and received the LHD's signed grant agreement, LHD will submit a request for naloxone kits on the Overdose Lifeline website. Overdose Lifeline will distribute kits containing naloxone to awarded applicants. It is recommended that LHDs request kits on a monthly or bimonthly basis since kits will not be delivered in bulk as they were in previous iterations of this grant.

Award recipients will be required to submit routine reports to Overdose Lifeline. Failure to submit the required reports will be deemed a termination for breach of grant agreement and shall entitle the Indiana Department of Health to suspend or cancel the remaining undelivered naloxone kits.

More detailed instructions on the dose request application and the distribution report will be included with the award notification.

Grant Agreement

Each organization that is awarded will be required to sign and complete a grant agreement. Naloxone kits will not be shipped until the signed grant agreement has been received and reviewed by IDOH.

OptIN Registration

Entities that disperse naloxone must be registered with OptIN, the state's naloxone entity website. Registered entities must review their organizational information on an annual basis. The site tracks where naloxone is dispersed throughout the state. The site also has multiple educational videos and resources.

- To register as a new entity, visit https://OptlN.in.gov/.
 - Select "Register as a New Naloxone Entity."
 - o Follow the prompts.
- Registered entities may update their information on file, submit their annual report or get a copy of the Indiana state health commissioner's standing order by visiting https://OptlN.in.gov/.
 - Select "Current Entities Only."
 - o Follow the prompts.



Points of Contact

For any questions or concerns, please contact the IDOH staff listed below:

Laura Hollowell, MA, LMHC Naloxone Program Manager Indiana Department of Health lhollowell@health.in.gov – (317) 234-2811

Brian Busching, MPH
Division Director
Indiana Department of Health
bbusching@health.in.gov – (317) 234-2865

